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OVER THE LAST 2 decades, buprenorphine has been used
for the treatment of pain, opioid addiction, and detoxification.
It has unique properties, including partial agonist activity at
the mu receptor, while also exhibiting antagonism at the kappa
receptor.1 The half-life is highly variable with each patient,
but it may extend up to 60 hours. In addition, even low doses
will outcompete other opioids to bind receptors, rendering
other opioids ineffective unless very high doses are used.2
Although this may be advantageous in the outpatient setting,
the pharmacokinetic and pharmacodynamic properties of
buprenorphine can complicate the perioperative management
of pain when these patients present for surgery. Herein, the
This case was presented in part at the Society of Cardiovascular Anesthesiologists 43rd Annual Meeting and Workshops.
1
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authors present a case during which a patient who was started
on buprenorphine for addiction therapy was referred subsequently for cardiac surgery during the same inpatient hospital
admission.
Case Report
A 31-year-old woman (45.5 kg) presented to the emergency
department with lethargy and abdominal pain. Emergency
medical services reported that they were dispatched for detoxification at the request of her family. Upon further questioning,
the patient acknowledged using intravenous heroin and methamphetamine and was febrile the day before (101.5˚F). Chest
radiography showed a left basilar consolidation concerning for
pneumonia, and blood cultures were positive for methicillinsensitive Staphylococcus aureus. An extensive workup subsequently was performed. A magnetic resonance imaging scan
of the brain was obtained due to altered mental status, which
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Fig 1. Pectointercostal fascial plane block in parasagittal ultrasound view. (A) Before injection of local anesthetic. (B) After successful injection of local anesthetic. IIM, internal intercostal muscle; LA, local anesthetic; PMM, pectoralis major muscle; Rib 2, costal cartilage of second rib. ***, block needle shaft.

showed numerous supratentorial and infratentorial infarcts
consistent with an embolic source. Computed tomography
with angiography of the head and neck was negative for any
evidence of a mycotic aneurysm. Treatment with oxacillin was
started for methicillin-sensitive Staphylococcus aureus bacteremia, which also was presumed to be the likely pathogen for
the pneumonia.
On hospital day 3, a transthoracic echocardiogram was
obtained, which showed multiple large echodensities involving
the mitral valve and subvalvular apparatus, as well as a small
vegetation on the tricuspid valve. Overall, the clinical picture
was concerning for infective endocarditis. Cardiac surgery
evaluated the patient and requested that a transesophageal
echocardiogram be obtained and also sought guidance from
neurology as to whether the high-dose anticoagulation
required for cardiopulmonary bypass would be permissible
given the recent cerebrovascular accidents from septic emboli.
On the same day, consultation was sought from psychiatry.
During this encounter, it became apparent that the patient had
been treated with buprenorphine in the past and was amenable
to restarting treatment. At the recommendation of psychiatry,
buprenorphine-naloxone, 2/0.5 mg, was initiated, which eventually was increased to 2 tablets (4 mg) 3 times daily.
A transesophageal echocardiogram was obtained on hospital
day 5, which showed complex mitral valve endocarditis,
including a 2.7 £ 1.4 cm vegetation on the mitral valve. Additionally, a 0.82 £ 1.2 cm tricuspid valve vegetation was seen.
There was mild-to-moderate mitral regurgitation and moderate
tricuspid regurgitation. The neurology team evaluated the
patient and determined that she was at low-to- moderate risk
for hemorrhagic conversion with systemic anticoagulation for
cardiopulmonary bypass. She subsequently was scheduled for
mitral and tricuspid valve repair versus replacement the following week.
On the day of surgery, the patient had been receiving buprenorphine therapy for about 2 weeks. A collaborative discussion
occurred among the anesthesia team caring for the patient
intraoperatively, the regional anesthesia team performing analgesic truncal blocks, and the acute pain team that would

participate in the patient’s postoperative care. Given the long
half-life of buprenorphine and the plan to resume buprenorphine postoperatively, a decision was made to provide multimodal analgesia without using a full mu-opioid agonist.
Preoperatively, the patient was given her usual dose of sublingual buprenorphine. Induction was performed with 3 mg of
midazolam, 100 mg of propofol, 150 mg of intravenous buprenorphine, and 100 mg of rocuronium. After intubation, bilateral pectointercostal fascial blocks (PIFB) were performed,
with a total of 30 mL of 0.25% bupivacaine with 2.5mg/mL
epinephrine, 1.67 mg/mL of clonidine, 0.1 mg/mL of preservative-free dexamethasone, and 5mg/mL of buprenorphine to
provide analgesia for sternotomy (Fig 1). In addition, rectus
sheath blocks were performed bilaterally, with a total of
20 mL of 0.25% bupivacaine with 1.67 mg/mL of clonidine,
2.5 mg/mL epinephrine, 0.1 mg/mL of preservative-free dexamethasone, and 5 mg/mL of buprenorphine to provide analgesia for the mediastinal drain. Before incision, 30 mg of
intravenous ketamine were administered, and a ketamine infusion was initiated at 0.5 mg/kg/hr. Overall, there was no significant sympathetic response to intubation, surgical incision,
sternotomy, or pericardiectomy. Cardiopulmonary bypass was
instituted, and the patient underwent mitral and tricuspid valve
repair. Separation from cardiopulmonary bypass was uneventful, and another 150-mg bolus of intravenous buprenorphine
was administered. A norepinephrine infusion ranging from 2to-7 mg/min was titrated for hypotension.
Postoperatively, her pain regimen included intravenous
ketamine and lidocaine infusions, as well as sublingual buprenorphine for medication-assisted treatment and as-needed
intravenous buprenorphine available for breakthrough pain.
She was extubated about 6 hours after arrival to the intensive
care unit, and her initial pain scores were 6-to-7 on a numeric
pain scale of 0-to-10, with 10 being the worst. Notably, she
reported a baseline pain score before surgery of 4. After extubation, she was transitioned to oral medications, including
scheduled acetaminophen, celecoxib, sublingual buprenorphine-naloxone, and gabapentin. Methocarbamol was prescribed as needed. She was able to participate in physical
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therapy on the day of extubation. She was transferred to the
hospital inpatient ward on postoperative day 3, and she subsequently was discharged from the hospital on postoperative day
5, with plans to complete 6 weeks of intravenous antibiotics.
She did not receive a single dose of a full mu-agonist during
the perioperative or postoperative period.
Discussion
This case conference highlights the continuation of buprenorphine and the avoidance of a full mu-opioid agonist during
cardiac surgery in a patient who recently was prescribed
buprenorphine for addiction therapy in an attempt to reduce
her risk of relapse after hospital discharge. When patients present for surgery on buprenorphine therapy, there are several different options for management.3 First, buprenorphine can be
continued, either at the current dose or at a lower dose, but can
be supplemented with higher doses of full opioid agonists in
an attempt to outcompete buprenorphine for the mu receptor.2
Leighton et al reported using this strategy by administering
intravenous hydromorphone to an obstetric patient taking
buprenorphine who received neuraxial anesthesia.3 These
authors believed that hydromorphone and sufentanil are the
opioids that are best suited to supplement buprenorphine due
to similar mu-receptor binding affinities. Regardless of
whether or not this strategy increases the risk for relapse, however, some patients specifically may request an anesthetic
without full mu-agonists out of fear of relapse.4 In these
patients, a second option is to continue buprenorphine and supplement with additional buprenorphine for surgical pain rather
than use full mu-agonists.3 This was the strategy used in this
patient. Finally, a third option is to discontinue buprenorphine
24-to-72 hours before surgery, depending on the dose, or possibly longer with high higher doses, with a plan to use traditional opioids.3 This strategy may not be ideal in a patient with
a substance use disorder as it may predispose them to relapse
of their opioid use disorder. Cardiac surgery itself has been
associated with persistent postoperative opioid use, even in
opioid-naı̈ve patients. In a large retrospective study of 25,673
patients undergoing coronary artery bypass grafting surgery
and 10,144 patients undergoing cardiac valve surgery, 10.2%
and 8.1% of patients were still using opioids 90-to-180 days
after surgery, respectively.5 Ultimately, the persistent use of
opioids after surgery in patients with a history of opioid use
disorder may contribute to the risk of relapse.2
The decision of which of these strategies to employ can be
challenging, as both the patients and anesthesiologists need to
balance complex dynamics. Patients may fear the stigma of
addiction therapy, experiencing pain perioperatively, and the
potential for relapsing.6 Anesthesiologists must consider these
concerns while also developing a plan to optimize perioperative analgesia. In order to provide guidance, multiple specialties, including the American Society of Regional Anesthesia
and Pain Medicine and the American Society of Anesthesiologists, issued recommendations on how to perioperatively manage buprenorphine. These groups suggested that
buprenorphine should not be interrupted routinely before
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surgery, although tapering down to a 16-mg total daily dose
may be reasonable for patients taking larger doses who are
expected to require high doses of opioids to treat surgical pain.
Weaning to a total daily dose of 16 mg has been shown to
leave 10%-to-20% of opioid receptors unbound by buprenorphine in pharmacokinetic studies.7 Should full mu-agonists be
needed, these recommendations suggested using fentanyl,
hydromorphone, or other opioids with similarly high receptor
binding. Otherwise, administering increased doses of buprenorphine may be effective, as it has inherent mu-opioid receptor activity. An acute pain consult can be helpful for
maximizing multimodal therapies, including, most importantly, nonopioid analgesics and regional anesthesia analgesic
procedures.6
After extensive discussion regarding the patient in this case,
the decision was made to continue her buprenorphine therapy
and use additional buprenorphine for acute pain rather than a
full mu-agonist. This strategy allowed her to maintain a medication-assisted treatment regimen continuously throughout the
perioperative period, as well as after discharge. In order to
optimize pain management, regional anesthesia was used
through the placement of truncal fascial plane blocks.
There are several different options for regional anesthesia in
patients who present for cardiac surgery by median sternotomy. In this patient, PIFB was used to provide analgesia at the
sternotomy site, and rectus sheath blocks were used for analgesia at the location of the mediastinal chest tube sites.8 PIFB targets the anterior branches of the intercostal nerves.9 Kumar
et al randomized patients undergoing cardiac surgery to
receive bilateral PIFB with 0.25% ropivacaine (n = 20) versus
control (n = 20).10 PIFB was performed at the conclusion of
surgery before transfer to the intensive care unit, and the average time to perform PIFB was 6 § 1.02 minutes. Resting pain
scores were significantly less in the PIFB group at 6 and
12 hours after extubation, but not at 0 or 3 hours. The PIFB
group also had lower rescue fentanyl requirements (0.82 §
0.19 mg/kg) compared to the control group (1.06 § 0.12 mg/
kg) (p < 0.001).10
Similarly, Khera et al conducted a randomized controlled
trial involving 80 patients undergoing cardiac surgery via
median sternotomy.11 The interventional group received PIFB
with 0.25% bupivacaine. Although pain scores were less in the
PIFB group (4.8 § 2.7 v 5.1 § 2.6, p < 0.001), there was no
significant difference in total opioid use in the first 48 hours.
Transversus thoracic muscle plane blocks (TTMPB) also
may be a useful regional anesthetic adjunct for patients undergoing cardiac surgery. Similar to PIFB but performed in the
adjacent fascial plane just deep to it, this technique similarly
targets the anterior branches of the intercostal nerves, thereby
providing analgesia to the anterior chest.9,12 In a randomized
controlled trial, Kaya et al compared TTMPB to PIFB before
surgical incision. In both cases, 20 mL of 0.25% bupivacaine
with epinephrine (1:400,000) was used, and both groups
allowed the surgeon to inject 10 mL of 0.25% bupivacaine at
the chest tube sites at the conclusion of surgery. There was no
statistically significant difference between the PIFB and
TTMPB groups regarding total morphine use at 24 hours
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(13.89 § 6.80 mg v 15.08 § 7.42, p = 0.608), which was the
primary outcome. Pain scores did not differ between the
groups, although the first request for an opioid occurred earlier
in the TTMPB group compared to the PIFB group (240 v 660
minutes, p = 0.002).12
Another potential regional anesthetic technique for cardiac
surgery via median sternotomy is the erector spinae (ESP)
block. The ESP block targets the dorsal and ventral rami of the
spinal nerves.9 In a randomized controlled trial, 30 patients
were divided into either the bilateral ESP block group with
20 mL of levobupivacaine (n = 15), or the sham block group
with 20 mL of normal saline (n = 15).13 The injection was performed before anesthetic induction. On average, the ESP group
had a lower amount of fentanyl equivalents used in the first
24 hours postoperatively (225 § 112 mg v 635 § 145 mg, p <
0.05), shorter duration of mechanical ventilation (88.4 §
17 min v 103.5 § 18 min, p < 0.05), and lower Ramsay sedation scores 6 hours after extubation (1.45 § 0.53 v 3.19 §
0.62, p < 0.05). Despite this, mean pain scores were not significantly different between the ESP and sham groups (3.67 §
1.41 v 4.50 § 1.00, p = 0.17).13 Another study similarly demonstrated a reduction in postoperative opioid use with ESP
blocks.14
Aside from the buprenorphine and regional anesthesia,
many other nonopioid adjuncts were used for this patient.
These included acetaminophen, gabapentin, and ketamine.
Notably, the effectiveness of these medications is debated. In a
randomized controlled trial that enrolled patients undergoing
coronary artery bypass surgery, an intraoperative bolus plus
infusion strategy for ketamine did not decrease pain scores or
reduce opioid consumption in the first 48 postoperative hours.
15
The use of gabapentinoids perioperatively also has been critiqued recently; although a meta-analysis found that gabapentinoids resulted in lower pain scores for the first 48 hours
postoperatively, the clinical significance of the effect was contested.16 Nevertheless, these medications still may be helpful
in opioid-tolerant patients.17
Although buprenorphine has been used in cardiac surgery
before, these prior reports differed in various ways. For example, some reports described the use specifically in the postoperative period.18,19 The authors reported that parenteral
buprenorphine provided effective analgesia, which may be
similar to morphine. Other groups reporting their use of buprenorphine during cardiac surgery also employed neuraxial techniques. For example, Samantaray et al conducted a trial
investigating the use of caudal buprenorphine in pediatric
patients undergoing cardiac surgery.20 Patients were randomized to receive either of the following with caudal anesthesia:
(1) 5 mg/kg of buprenorphine with intravenous fentanyl available as a rescue based on hemodynamics, or (2) intravenous
fentanyl boluses throughout the case. After the patients awoke,
the authors demonstrated lower mean pain scores for the first
24 hours in the children who received caudal analgesia (2.5 §
1.2 v 4.6 § 1.7, p = 0.004). Notably, the doses of fentanyl
between the groups were not provided, but it was stated that
the number of rescue doses was similar between the 2
groups.20 Alalade et al reported a case in which a patient

maintained on buprenorphine therapy underwent pulmonary
valve replacement via median sternotomy.4 This patient
received nonopioid adjuncts and had his daily buprenorphine
dose titrated in the perioperative period. Their case differed
from the one presented in this case conference in that their
patient received a thoracic epidural.
One trial that involved the administration of buprenorphine
intraoperatively was reported by Okutani et al21 In this study,
20 adult patients were randomized into 2 equal groups. One
group received 6 mg/kg of buprenorphine, whereas the other
group received 12 mg/kg of buprenorphine. These patients also
received diazepam and nitrous oxide. Halothane was added during episodes of hypertension in 60% of the patients in the 6 mg/
kg group, and in 40% of the patients in the 12 mg/kg group.
Both groups received an additional 6 mg/kg of buprenorphine
when cardiopulmonary bypass was instituted. The authors
reported that 6 mg/kg was inadequate to blunt the catecholamine response during cardiac surgery, but the 12 mg/kg group
performed better in this regard. Analgesia, therefore, was
assumed to be superior in the 12- mg/kg group. There are several points worth noting about this trial. First, all patients
received a bolus of 0.15 mg/kg of morphine sulfate as premedication; therefore, the trial differed from the authors' patient in
that it involved a full mu-opioid agonist. Second, plasma levels
of buprenorphine were measured in 4 patients, and the peak was
reported to be 5 minutes after administration. Third, there was a
higher concentration of antidiuretic hormone in the 12-mg/kg
group, which led the authors to postulate that buprenorphine
may lead to increased secretion of antidiuretic hormone.21
In summary, the authors present a case during which a patient
who was initiated recently on buprenorphine therapy was maintained successfully on buprenorphine throughout the perioperative period for cardiac surgery. Full mu-opioid agonists were
avoided by using multiple adjuncts, including nonopioid pharmacologic agents and regional anesthesia techniques. This multimodal analgesic plan ultimately facilitated achieving
satisfactory pain management and hemodynamic control intraoperatively. By collaborating with the acute pain team, she was
maintained on her buprenorphine regimen postoperatively, and
she was discharged without interruption of therapy with the
goal of minimizing her risk of relapse.
Expert Commentary (Dr. Khalil, Dr. Sanders, Dr. Sibai)
Postoperative pain after cardiac surgery is a significant factor that can affect patients’ short-term morbidity, as well as
long-term rehabilitation and quality of life.22 Although significant advances in treating acute pain from cardiothoracic procedures through implementing institutional protocols that use
multimodal pain regimens have been made, individual
approaches need to be considered for patients who may have
unique medical histories and perioperative courses.
Variations in postoperative pain levels have been noted
among different patient populations and to result from different cardiothoracic procedures.23 Higher pain scores have been
seen in female patients, younger patients, and those with preexisting psychologic disorders. Procedures that are more
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invasive with larger incisions, longer in duration, as well as
those that require postoperative drains or use cardiopulmonary
intraoperative bypass, also have been shown to lead to higher
postoperative pain levels.
The mechanism of pain after cardiac surgery is multifactorial. The chest wall is innervated by T1-to-T11 thoracic intercostal nerves, with possible sensory contribution by the
pectoral, long thoracic, and thoracodorsal nerves. Tissue
trauma from skin incision, sternotomy, and harvesting of grafts
leads to local neurogenic inflammation and irritation of local
nociceptors.24 Cardiopulmonary bypass leads to further release
of inflammatory mediators and can aggravate the perception of
pain. Postoperative pain also has a musculoskeletal component
from sternal retraction, presence of irritant tubes, and prolonged bed rest. This leads to multiple physiologic changes,
including limitations in pulmonary function, intense sympathetic activation, and changes in the endocrine system, affecting every organ and complicating recovery.
An accurate assessment of acute pain with the use of pain
scales is crucial for deciding on treatment strategies that will
prevent the development of chronic postoperative pain, and
should take into account a patient’s pain at rest and during
movement. A longer duration of severe pain in the immediate
postoperative period has been shown to be correlated with the
risk of developing chronic pain—with every 10% increase in
time spent in severe pain, the risk of developing chronic pain
increases by 30%.25 Chronic pain has been seen in 21%-to55% of patients who have undergone cardiac surgical procedures, with 17% reporting pain >2 years from their initial
surgery.26
The methods used for postoperative analgesia aim to optimize patient comfort and facilitate the recovery process. A balanced multimodal approach that includes the use of
pharmacologic and nonpharmacologic techniques maximizes
benefits while limiting adverse effects. Nonopioids, such as
acetaminophen, gabapentinoids, and muscle relaxants, can
improve pain scores in patients receiving both patient-controlled and nurse-controlled opioid administration.27 The use
of regional techniques has grown in popularity, with favorable
outcomes seen in postcardiac surgery pain control with the use
of epidural, paravertebral, intercostal, pectoralis, serratus, and
erector spinae nerve blockade through single-shot and continuous catheter usage. The authors used a multimodal approach,
combining scheduled celecoxib, acetaminophen, gabapentin,
and methocarbamol, as needed, with bilateral pectointercostal
fascial plane and rectus sheath blocks.
Working within the context of an ongoing opioid epidemic,
physicians are more likely to encounter patients who have an
opioid use disorder (OUD), are receiving treatment for OUD,
or are seeking opioid treatment initiation perioperatively or
during hospital admission. or Several efforts have been made
to identify the most appropriate approach to acute pain management for patients who are on maintenance therapy for
OUD and within the inpatient and perioperative settings. The
focus should be on finding a balance between adequately controlling pain and preventing withdrawal or relapse during the
hospital admission and after discharge.
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Buprenorphine, a partial agonist at the mu-opioid receptor
and a kappa receptor antagonist, is approved by the United
States Food and Drug Administration for the treatment of
OUD and pain. It has a higher binding affinity at the mu-receptor than hydromorphone, morphine, fentanyl, and oxycodone.28 The half-life of buprenorphine has broad interpatient
variability, ranging from 3 hours with intravenous administration to 24-to-60 hours when sublingually given.29 The analgesic half-life of buprenorphine is shorter than the half-life of the
drug, resulting in a need for different dosing regimens based
on the indication—3 or 4 times daily dosing for analgesia and
once or twice daily dosing for OUD.30
Although buprenorphine is a partial mu-opioid receptor agonist, it is still a potent analgesic. As was evident with the patient
in this case, pain control was adequate with a continuation of
the preoperative buprenorphine dose, additional doses for breakthrough pain, and use of multimodal analgesia. The parenteral
formulation of buprenorphine can be administered intramuscularly or intravenously at a dose of 0.3 mg every 6 hours for the
management of moderate-to-severe acute pain.31
Intraoperative use of buprenorphine at a dose of 4 mg/kg,
with incremental dosing of half the initial dose, previously has
been shown to provide satisfactory analgesia as part of a balanced anesthetic technique, with an observed prolonged duration of action into the postoperative period.32 The authors have
demonstrated successfully that pain management and sympathectomy were achievable with the continuation of buprenorphine, intraoperative use of buprenorphine as the sole opioid
agonist, and the use of multimodal analgesia.
Although previously published expert opinions and practice
guidelines have recommended discontinuing preoperative
buprenorphine use in patients with OUD for concern of inadequate postoperative pain control,2,33 recent research has shown
that stopping buprenorphine preoperatively can increase the
risk of relapse and withdrawal.34
In 2020, the American Society of Addiction Medicine published a national practice guideline-focused update that recommended against discontinuing buprenorphine for patients with
OUD before surgery, and stated that higher potency intravenous full agonist opioids can be used perioperatively for analgesia. The publication also mentioned that patients who are on
buprenorphine for OUD and who have acute moderate-tosevere pain may benefit from the addition of buprenorphine
doses as needed.35 This is in line with the management
approach that the authors appropriately followed when they
continued their patient on perioperative buprenorphine and
added as-needed doses in order to decrease the risk of relapse
and withdrawal.
Preoperatively tapering buprenorphine has been a topic of
debate, resulting in variable recommendations. Research has
shown that mu-receptor availability varies depending on the
dose of buprenorphine—a 16- mg sublingual dose can occupy
79%-to-95% of mu-opioid receptors, and doses greater than
24-to-32 mg can occupy up to 95% of receptors. Thus, some
receptors remain unoccupied and available for full mu-agonist
binding.31,36,37 Recommendations for patients who are on
high-dose buprenorphine (>16 mg) with anticipated
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moderate-to-severe postoperative pain or higher opioid
requirements included the following: tapering down the home
dose of buprenorphine to 16 mg before surgery, administering
8 mg of buprenorphine on the morning of surgery, maintaining
with 8 mg daily or 4 mg twice daily, adding full opioid agonists as needed, and discontinuing short-acting opioids/returning to the home-dose buprenorphine as soon as possible.31,38
Case reports and studies on receptor availability showed that
adequate pain control still can be achieved even for patients
who are on high-dose buprenorphine. Further research is
required to identify the percentage of opioid receptors that
need to be occupied by partial or full mu-opioid receptor agonists to achieve adequate analgesia or if effective drug-binding
saturation differs from one patient to another. Not all hospitals
across the United States have access to pain and OUD specialists, so any changes to a patient’s home dose of buprenorphine
before a surgical procedure should be discussed with the
patient and the primary buprenorphine prescriber to weigh
benefits against risks, including potential relapse during or
after discharge.36 Furthermore, the perioperative period is a
vulnerable time for patients, and patients with substance use
disorder may experience more anxiety about inadequate pain
relief, withdrawal, and relapse. They also may have increased
sensitivity to pain, lowered pain tolerance, and chronic pain
conditions compared to opioid-naive patients. Anxiety can
trigger craving and is associated with higher opioid misuse in
patients who have a history of substance use disorder.39 Therefore, recent expert opinion endorses avoiding preoperative
tapering of buprenorphine.36
A multisociety expert panel that included members of the
American Society of Regional Anesthesia and Pain Medicine,
the American Society of Anesthesiologists, the American
Academy of Pain Medicine, the American Society of Addiction Medicine, and the American Society of Health System
Pharmacists, recently has published recommendations for
buprenorphine management in the perioperative period that
are based on expert opinion and an assessment of the literature,
and were derived using a modified Delphi process. The recommendations included the following: avoiding buprenorphine
taper, using multimodal analgesia, incorporating regional
anesthesia techniques if possible, dividing the home dose of
buprenorphine into 2 or 3 times per day if needed to provide
analgesia for mild-to-moderate pain, increasing buprenorphine
dose to 24-to-32 mg given in divided doses or using 0.3 mg
intravenously every 6 hours as needed for severe pain, adding
a high-affinity full mu-agonist (fentanyl or hydromorphone) if
acute pain persists, monitoring patients closely when adding
opioids or increasing buprenorphine dose, creating a postdischarge plan to taper off the added full mu-agonist, and returning to preoperative buprenorphine maintenance dose in
coordination with the primary buprenorphine prescriber. The
panel also recommended against the routine preoperative discontinuation of buprenorphine.36
Therefore, the authors here agree with the authors on their
strategy of continuing the patient’s preoperative buprenorphine
dose, using multimodal analgesia (celecoxib, acetaminophen,
gabapentin, and methocarbamol as needed), implementing

regional techniques (lateral pectointercostal fascial plane and
rectus sheath blocks), administering the intraoperative use of
buprenorphine, using postoperative ketamine and lidocaine
infusions, and providing additional doses of buprenorphine for
breakthrough pain.
Expert Commentary (Dr. Hong, Dr. Kiwakyou, Dr. Brodt)
In this case conference, the authors described a unique and
personalized perioperative pain regimen for a patient with
comorbid OUD undergoing double-valve surgery for endocarditis, using continuation of preoperative buprenorphine with
supplemental parenteral doses, multimodal analgesia, and fascial plane blocks.
Anesthesiologists and other perioperative healthcare providers increasingly need to manage patients on addiction therapy for OUD. In this vulnerable population, the physician’s
responsibility extends beyond providing safe and effective perioperative analgesia to mitigate the risk of relapse that may occur
with routine perioperative opioid management. The management described in this case report is notable for the use of parenteral buprenorphine, with the objective of uninterrupted
addiction therapy and avoidance of full mu-opioid agonists.
Buprenorphine is a mixed agonist-antagonist opioid approved
for opioid detoxification, opioid maintenance, and pain management. Due to high binding affinity with partial agonism, as well
as a prolonged dissociation at the mu-receptor, buprenorphine is
effective at blocking other mu-agonists and has a more limited
effect on respiratory depression and euphoria, making it wellsuited for addiction therapy.40-43 In contrast to naltrexone, an
opioid antagonist also used for OUD, the mixed-receptor activity of buprenorphine means that if therapy is discontinued
abruptly, patients are at risk for withdrawal in addition to
relapse. No consensus exists in the literature regarding the perioperative continuation of buprenorphine. Some case reports
described patients on buprenorphine therapy who were unable
to achieve adequate postoperative pain control until after their
buprenorphine was discontinued,44-48 although others reported
adequate analgesia with the continuation of buprenorphine.49,50
Management recommendations vary51,52 and include discontinuing buprenorphine at least 72 hours before surgery and replacing it with full mu-receptor agonists to prevent withdrawal,
replacing buprenorphine with methadone, supplementing with
high-dose opioids, or dividing the total daily dose of buprenorphine into a 6- or 8-hour dosing schedule to provide more durable analgesia. If mu-receptor agonists are needed, sufentanil,
fentanyl, or hydromorphone usually are chosen, given their
higher binding affinities,53 but there is evidence of an increased
risk of abuse and potential relapse for patients with OUD
exposed to additional opioids.4,54 Hence, the appeal of the
authors’ approach—the combination of parenteral buprenorphine and ongoing sublingual buprenorphine, avoided exposure
to additional opioid agonists while also avoiding interruption of
addiction therapy.
In addition to a personalized and novel approach to buprenorphine dosing, the authors used regional anesthesia with single-shot fascial plane blocks, as well as multimodal nonopioid

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on October 11, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

R.J. Fernando et al. / Journal of Cardiothoracic and Vascular Anesthesia 36 (2022) 37013708

analgesia. Fascial plane blocks have grown in both number and
acceptance as an analgesic adjuvant in cardiothoracic surgery
in the past few years,9,55 and although evidence on the degree
of benefit to patients still is accumulating, these techniques are
an appealing addition for patients with compelling reasons to
reduce opioid exposure. The specific application of fascial
plane blocks varies widely depending on local expertise and
resources, and techniques may be classified broadly as singleshot, catheter-based, or rescue blocks. The authors used preincision single-shot superficial parasternal intercostal plane and
rectus sheath blocks, which target the anterior branches of the
T2-to-T6 intercostal and the T7-to-T11 thoracic nerves,
respectively, followed by a postoperative systemic lidocaine
infusion. In contrast to the novel and appealing use of buprenorphine described by the authors, the inability to provide a
more durable regional technique, usually achieved with catheter-based techniques or repeated blocks, is an area that the
authors recommended for further consideration and refinement. Readers are referred to an excellent article describing
standardized nomenclature for chest and abdominal wall
blocks,56 and encouraged to connect with colleagues through
the Society of Cardiovascular Anesthesiologists or American
Society of Regional Anesthesiologists special interest groups
for “boots on the ground” discussions of pathways and implementation of regional anesthesia in cardiac surgery.
This case report outlined an important and appealing management strategy for patients with OUD on buprenorphine
coming for cardiac surgery. The authors are commended for
their management of this complex case, particularly for avoiding exposure to potent opioid agonists and interruption of
addiction therapy, thus demonstrating the feasibility of using
buprenorphine as the sole opioid for intraoperative and postoperative pain management in cardiac surgery. The authors are
hopeful for further advances in the anesthetic management of
patients with OUD and welcome this case conference as an
example of what this future may be.
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None.
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